That question probably warrants a whole study of its own, so I could not possibly do justice to the possible problems and potential answers.
All I would say is that this is something the Government of Canada has put thought into. It was raised, as part of the pan-Canadian action plan, through the proposal of a pull incentive. That is one of the avenues that are being explored in Canada and elsewhere.
Beyond that, I think there are many other structural barriers, certainly in what the replacements are for pharmaceutical companies to develop drugs and provide clinical trials. There are multinational and international initiatives, such as GARDP or CARB-X, that are trying to stand in lieu of what pharmaceutical companies used to do. The next few years will tell us whether this will be successful or not.
